Robert Musslewhite

Robert Musslewhite is currently Chairman of the Governors Board at St. Albans School since 2013.
He serves as Independent Director at CoStar Group, Inc. since 2019, Director at Ascend Learning LLC since 2018, Director at Miriam’s Kitchen, Director at Immunomedics, Inc. since 2020, Director at ADC Therapeutics America, Inc. since 2023, Director at Iodine Software LLC since 2022, Independent Director at Cardinal Health, Inc. starting 2025, Member of The Economic Club of Washington, and Member of the Young Presidents' Organization (Washington) local chapter.
Former roles include Chairman & Chief Executive Officer at The Advisory Board Co. from 2013 to 2017, Chief Executive Officer at OptumInsight, Inc. from 2019 to 2022, Chief Executive Officer at Optum360 LLC in 2019, President & Chief Executive Officer at Lundbeck Seattle BioPharmaceuticals, Inc. from 2018 to 2019, President & Chief Executive Officer at Climb Bio, Inc. from 2020 to 2023, Chairman & Chief Executive Officer at The Advisory Board Co. (United Kingdom) from 2017 to 2019, Chief Executive Officer & Director at Definitive Healthcare Corp.
from 2022 to 2024, Director at SNL Financial LC, Director at Evolent Health, Inc. from 2011 to 2016, Director at Clovis Oncology, Inc. from 2018 to 2022, President & Director at Definitive Healthcare LLC from 2021 to 2022, Director at Chinook Therapeutics, Inc., Director at Autolus Therapeutics Plc, Associate Principal at McKinsey & Co., Inc. from 1997 to 2003, and Chief Commercial Officer & Executive VP at Juno Therapeutics, Inc. from 2015 to 2018.
Education includes an undergraduate degree from Princeton University conferred in 1992 and a graduate degree from Harvard Law School conferred in 1996.